Mikko Mannerkoski, MSc (Tech), MBA
Mannerkoski is the Chairman of the Board of Aranda. Mikko brings Aranda over 20
years of experience in helping create and execute on value-creation strategies.
He initially worked in investment banking advising major corporate and private
equity clients in mergers & acquisitions and capital market transactions.
He rose to a leadership position in what was at the time a leading corporate
finance advisory in Northern Europe before setting on an entrepreneurial track.
For the past 10 years Mikko has been active in the life-science field as a
founder and shareholder in a handful of companies in the US and in Finland that
work in radiation oncology, immune-oncology, antibody-drug conjugates and
diagnostics. Mikko has a M.Sc. from Helsinki University of Technology
(currently Aalto University, Department of Bioproducts and Biosystems) and
M.B.A. in finance from the Helsinki School of Economics with studies at the
Ross School of Business of the University of Michigan. Currently Mikko is CFO
at Rappta Therapeutics Ltd.
Erkki Tenhunen is a Board member of Aranda. Erkki brings Aranda 25 years of expertise in high technology start-up companies, fundraising, business development and commercialization of drug development and MedTech projects. He started his career in life-sciences by co-founding Contral Pharma that developed a drug against alcoholism. The company was later listed on the Helsinki Stock Exchange subsequently sold to a US acquirer in a public tender offer. Erkki has later co-founded several companies developing radiation therapy equipment and anti-cancer pharmaceutical technologies. Currently Erkki is head of Business Development at Rappta Therapeutics Ltd.